Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870401 | 0.73 | NPC1 (0.55) | NPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4168050 | 0.71 | NPC1 (0.53) | NPC1RAB9AGAAHCAR2KMT2A | |
| SCHEMBL30226131 | 0.70 | NPC1 (0.51) | NPC1RAB9AGAADYRK1AHCAR2 | |
| SCHEMBL4795587 | 0.67 | NPC1 (0.48) | NPC1RAB9AGAAKMT2A | |
| SCHEMBL5876509 | 0.62 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2WNT1DYRK1A | |
| SCHEMBL22482202 | 0.61 | NPC1 (0.45) | NPC1RAB9AGAASMN1; SMN2RXFP1 | |
| SCHEMBL22518533 | 0.60 | HCAR2 (0.64) | NPC1RAB9AGAASMN1; SMN2RXFP1 | |
| SCHEMBL22518545 | 0.60 | HCAR2 (0.64) | NPC1RAB9AGAASMN1; SMN2RXFP1 | |
| SCHEMBL4792038 | 0.59 | NPC1 (0.61) | NPC1RAB9AWNT1DYRK1ASMYD3 | |
| SCHEMBL18131065 | 0.59 | TSHR (0.65) | NPC1RAB9AGAASMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | NPC1 1992/4885RAB9A 440/4885GAA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.